☆ 4.2 Letter

Prevalence of the JAK2 V617F and MPL Mutations in Stroke, Abdominal and Peripheral Venous Thrombosis

ACTA HAEMATOLOGICA (2010)

期刊

ACTA HAEMATOLOGICA

卷 124, 期 3, 页码 160-161

出版社

KARGER

DOI: 10.1159/000320171

关键词

-

类别

Hematology

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Hematology

Cerebral venous thrombosis and myeloproliferative neoplasms: A three-center study of 74 consecutive cases

Naseema Gangat, Paola Guglielmelli, Silvia Betti, Faiqa Farrukh, Alessandra Carobbio, Tiziano Barbui, Alessandro M. Vannucchi, Valerio De Stefano, Ayalew Tefferi

Summary: The study retrospectively reviewed 74 cases of CVT associated with MPNs, revealing a close association with JAK2V617F, younger age, and female gender. MPN-associated CVT had a lower likelihood of concurrent venous thromboses and intracerebral hemorrhage compared to COVID vaccine-related CVT, making it non-fatal.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

添加到收藏夹

Article Clinical Neurology

Clinical Characteristics and Management of Cerebral Venous Sinus Thrombosis in Patients with Essential Thrombocythemia

Lidong Jiao, Xiaoqin Huang, Chunqiu Fan, Hong Zhao, Zhen Li, Huixin Shen, Jian Chen, Jiangang Duan

Summary: The study found that about one-third of ET patients have CVST, who are typically younger and less likely to have cardiovascular risk factors such as hypertension and coronary artery disease. Patients with CVST have lower platelet counts and are at higher risk of thrombosis.

NEUROPSYCHIATRIC DISEASE AND TREATMENT (2021)

添加到收藏夹

Article Medicine, General & Internal

A Comparison of Bone Marrow Morphology and Peripheral Blood Findings in Low and High Level JAK2 V617F Allele Burden

Emina Babarovic, Blazen Marijic, Luka Vranic, Josipa Ban, Toni Valkovic, Ita Hadzisejdic

Summary: Cases with low level JAK2 V617F mutations may present with normal looking megakaryocytes without atypia, while those with high JAK2 V617F mutation burden often have atypical megakaryocytes with clustering and maturation defects. Platelet count and hematocrit levels differ significantly between JAK2 V617F <3% and ≥3% mutation burden. Close follow-up is necessary for patients with low JAK2 V617F positivity due to the morphological changes observed in the bone marrow.

DIAGNOSTICS (2023)

添加到收藏夹

Article Biophysics

Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT

Juan Carlos Hernandez-Boluda, Diderik-Jan Eikema, Linda Koster, Nicolaus Kroeger, Marie Robin, Moniek de Witte, Juergen Finke, Maria Chiara Finazzi, Annoek Broers, Ludek Raida, Nicolaas Schaap, Patrizia Chiusolo, Mareike Verbeek, Carin L. E. Hazenberg, Kazimierz Halaburda, Aleksandr Kulagin, Helene Labussiere-Wallet, Tobias Gedde-Dahl, Werner Rabitsch, Kavita Raj, Joanna Drozd-Sokolowska, Giorgia Battipaglia, Nicola Polverelli, Tomasz Czerw, Ibrahim Yakoub-Agha, Donal P. Mclornan

Summary: In this study, the outcomes of allo-HCT in 346 CALR-mutated MF patients were analyzed. The results showed that CALR-mutated patients had better overall survival rates compared to other molecular subtypes. These findings have important implications for predicting survival after transplantation in MF patients.

BONE MARROW TRANSPLANTATION (2023)

添加到收藏夹

Article Genetics & Heredity

Low JAK2 V617F Allele Burden in Ph-Negative Chronic Myeloproliferative Neoplasms Is Associated with Additional CALR or MPL Gene Mutations

Tatiana Makarik, Adhamjon O. Abdullaev, Elena E. Nikulina, Svetlana A. Treglazova, Elena E. Stepanova, Irina N. Subortseva, Alla M. Kovrigina, Anait L. Melikyan, Sergei M. Kulikov, Andrey B. Sudarikov

Summary: JAK2 V617F, CALR exon 9, and MPL exon 10 mutations are commonly associated with Ph-negative chronic myeloproliferative neoplasms. Despite lacking selective advantage for clonal expansion after one mutation emerges, simultaneous findings of these mutations have been reported in a small percentage of cases.

GENES (2021)

添加到收藏夹

Article Pathology

Comparison of Clinical and Molecular Features Between Patients With Essential Thrombocythemia and Early/Prefibrotic Primary Myelofibrosis Presenting With Thrombocytosis in Taiwan

Ming-Chung Kuo, Wen-Yu Chuang, Hung Chang, Tung-Huei Lin, Jin-Hou Wu, Tung-Liang Lin, Che-Wei Ou, Yu-Shin Hung, Ting-Yu Huang, Ying-Jung Huang, Po-Nan Wang, Lee-Yung Shih

Summary: This study aimed to investigate the clinical and prognostic relevance of distinguishing pre-PMF-T from ET. Results showed that pre-PMF-T patients had older age, higher leukocyte and platelet counts, but lower hemoglobin levels compared to ET patients. Pre-PMF-T patients had lower overall, leukemia-free, and thrombosis-free survival rates. The presence of JAK2 (V617F) mutation was significantly associated with pre-PMF-T.

AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2023)

添加到收藏夹

Article Hematology

A STAT5B-CD9 axis determines self-renewal in and leukemic stem cells

Sebastian Kollmann, Reinhard Grausenburger, Thorsten Klampfl, Michaela Prchal-Murphy, Klavdija Bastl, Hanja Pisa, Vanessa M. Knab, Tania Brandstoetter, Eszter Doma, Wolfgang R. Sperr, Sabine Lagger, Matthias Farlik, Richard Moriggl, Peter Valent, Florian Halbritter, Karoline Kollmann, Gerwin Heller, Barbara Maurer, Veronika Sexl

Summary: STAT5B plays a unique role in driving self-renewal of hematopoietic and leukemic stem cells, specifically activating genes associated with quiescence and self-renewal, including CD9. CD9 levels serve as a prognostic marker for patients with STAT5-driven leukemia, and anti-CD9 antibodies may be useful in targeting and eliminating leukemic stem cells. Consideration of STAT5A and STAT5B as distinct entities is crucial in normal and malignant hematopoiesis.

BLOOD (2021)

添加到收藏夹

Article Peripheral Vascular Disease

JAK2 V617F Mutation and Large Cerebral Artery Disease in Patients with Myeloproliferative Neoplasms

Naoki Oyama, Takanori Iwamoto, Keito Doyu, Saki Miyazato, Tomoko Okazaki, Seiko Yamada, Toshinori Kondo, Hideho Wada, Yoshiki Yagita

Summary: The aim of this study was to investigate the association between JAK2 V617F mutation and LCAD in patients with MPNs. Retrospective analysis revealed a significant association between JAK2 V617F mutation and LCAD. This suggests that JAK2 V617F mutation may play a role in promoting cerebrovascular atherosclerosis and could be crucial in determining therapeutic strategies for both JAK2 V617F mutated MPNs and LCAD-related stroke.

JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2023)

添加到收藏夹

Review Clinical Neurology

Venous stroke-a stroke subtype that should not be ignored

Yifan Zhou, Huimin Jiang, Huimin Wei, Lu Liu, Chen Zhou, Xunming Ji

Summary: This article reviews the pathophysiological mechanisms and clinical features of stroke, focusing on arterial stroke and cerebral venous thrombosis. It provides guidance for further research on cerebral venous thrombosis and summarizes the etiology, epidemiology, symptomatology, diagnosis, and treatment heterogeneity of this condition.

FRONTIERS IN NEUROLOGY (2022)

添加到收藏夹

Article Hematology

Prevalence of definite antiphospholipid syndrome in carriers of the JAK2V617F mutation

Snjezana Janjetovic, Lennart Beckmann, Katharina Holstein, Christina Rolling, Benjamin Thiele, Philippe Schafhausen, Gerhard Schoen, Carsten Bokemeyer, Florian Langer, Minna Voigtlaender

Summary: The study identified a significant association between JAK2V617F-positive MPN and definite APS, with patients with APS potentially experiencing earlier onset of thrombotic events, necessitating more aggressive antithrombotic treatment strategies.

THROMBOSIS RESEARCH (2021)

添加到收藏夹

Article Clinical Neurology

Outcome Prediction in Cerebral Venous Thrombosis: The IN-REvASC Score

Piers Klein, Liqi Shu, Thanh N. Nguyen, James E. Siegler, Setareh Salehi Omran, Alexis N. Simpkins, Mirjam Heldner, Adam de Havenon, Hugo J. Aparicio, Mohamad Abdalkader, Marios Psychogios, Maria Cristina Vedovati, Maurizio Paciaroni, Rascha von Martial, David S. Liebeskind, Diana Aguiar de Sousa, Jonathan M. Coutinho, Shadi Yaghi

Summary: Risk factors for poor neurological outcome in patients with cerebral venous thrombosis were identified, and a prognostic score was derived and validated. This score showed better accuracy in predicting poor outcomes compared to existing scoring systems and could be useful for clinical decision making and targeted therapy.

JOURNAL OF STROKE (2022)

添加到收藏夹

Article Oncology

SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice

Christophe Willekens, Lucie Laplane, Tracy Dagher, Camelia Benlabiod, Nicolas Papadopoulos, Catherine Lacout, Philippe Rameau, Cyril Catelain, Alexia Alfaro, Valerie Edmond, Nicolas Signolle, Valentine Marchand, Nathalie Droin, Remco Hoogenboezem, Rebekka. K. K. Schneider, Alex Penson, Omar Abdel-Wahab, Stephane Giraudier, Florence Pasquier, Caroline Marty, Isabelle Plo, Jean-Luc Villeval, Stefan. N. N. Constantinescu, Francoise Porteu, William Vainchenker, Eric Solary

Summary: Heterozygous mutation in SRSF2(P95H) and JAK2(V617F) is associated with some myeloproliferative neoplasms, especially primary myelofibrosis. In this study, it was found that Srsf2(P95H) mutation can delay myelofibrosis induced by Jak2(V617F) and decrease TGF beta 1 serum level. Furthermore, Srsf2(P95H) mutation reduces the competitiveness of transplanted Jak2(V617F) hematopoietic stem cells while preventing their exhaustion. These findings highlight the role of JAK2 exon 14 skipping promotion in reducing JAK/STAT signaling in pathological conditions.

LEUKEMIA (2023)

添加到收藏夹

Article Immunology

Analysis of JAK2 V617F mutation in Tunisian patients with myeloproliferative neoplasms

Soumaya Chadi, Tarak Dhaouadi, Imen Sfar, Hela Baccouche, Rym Nabli, Neila Ben Romdhane, Taieb Ben Abdallah, Yousr Gorgi

Summary: The prevalence of JAK2 V617F mutation is higher in Tunisian patients with MPN, especially in those with polycythemia vera. This mutation is significantly associated with hemoglobin levels, hematocrit, and thrombosis occurrence in MPN patients, with a particularly predictive value for thrombosis in essential thrombocythemia patients carrying the mutation.

EUROPEAN JOURNAL OF INFLAMMATION (2021)

添加到收藏夹

Article Clinical Neurology

Epidemiology, Clinical Features, and Outcome in a Cohort of Adolescents With Cerebral Venous Thrombosis

Julia Devianne, Nicolas Legris, Isabelle Crassard, Celine Bellesme, Yannick Bejot, Celine Guidoux, Fernando Pico, David Germanaud, Michael Obadia, Diana Rodriguez, Philippe Tuppin, Manoelle Kossorotoff, Christian Denier

Summary: Cerebral venous thrombosis (CVT) in adolescents is rare and complex, with differences in clinical presentation and associated conditions between sexes, and more severe outcomes than in adults. Specialized management and follow-up are recommended.

NEUROLOGY (2021)

添加到收藏夹

Article Clinical Neurology

Thyroid dysfunction in cerebral venous thrombosis: a retrospective cohort study

Simon Fandler-Hoefler, Stefan Pilz, Marion Ertler, Melanie Haidegger, Markus Kneihsl, Gerit Wuensch, Thomas Gary, Christian Enzinger, Thomas Gattringer

Summary: This study investigated the frequency and clinical characteristics of thyroid dysfunction in CVT patients, finding a high prevalence of thyroid dysfunction in CVT patients including both hyperthyroidism and hypothyroidism. Further studies are needed to determine if there is a causal relationship, but screening for TSH in CVT patients is recommended due to the frequent coexistence of the two diseases.

JOURNAL OF NEUROLOGY (2022)

添加到收藏夹

Editorial Material Medicine, General & Internal

Reduction in molecular diagnostics of myeloproliferative neoplasms during the COVID-19 pandemic

Stephen E. Langabeer

IRISH JOURNAL OF MEDICAL SCIENCE (2021)

添加到收藏夹

Letter Pathology

Real-world experience of BRAF V600E mutation testing in hairy cell leukaemia

Stephen E. Langabeer, David O'Brien, Sarah McCarron, C. Larry Bacon, Elisabeth Vandenberghe

JOURNAL OF CLINICAL PATHOLOGY (2021)

添加到收藏夹

Letter Oncology

Prevalence of atypical BCR-ABL1 transcript types in adult Philadelphia chromosome-positive acute lymphoblastic leukemia: implications for measurable residual disease

Una Bhreathnach, Laura Kearney, Stephen E. Langabeer

HEMATOLOGY TRANSFUSION AND CELL THERAPY (2022)

添加到收藏夹

Letter Hematology

Quantification of atypical BCR-ABL1 fusion transcripts in patients with chronic myeloid leukemia: Which approach for harmonization?

Una Bhreathnach, Stephen E. Langabeer

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2022)

添加到收藏夹

Letter Medical Laboratory Technology

Testosterone, erythrocytosis and the JAK2 V617 F mutation

Stephen E. Langabeer

ANNALS OF CLINICAL BIOCHEMISTRY (2022)

添加到收藏夹

Letter Dermatology

Pyoderma gangrenosum and myeloproliferative neoplasms

Stephen E. Langabeer

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2023)

添加到收藏夹

Letter Hematology

Frequency and driver mutation diversity of concomitant chronic myeloid leukemia and Philadelphia chromosome-negative myeloproliferative neoplasm

Stephen E. Langabeer, Alfred Jones, Eibhlin Conneally, Helen Enright, Philip Murphy, Kanthi Perera, John Quinn, Patrick Thornton

INTERNATIONAL JOURNAL OF HEMATOLOGY (2023)

添加到收藏夹

Letter Hematology

Persisting with persistent thrombocytosis

Stephen E. Langabeer, Aine Burke

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2023)

添加到收藏夹

Letter Pathology

BCR::ABL1 screening is not indicated in patients with splenomegaly without neutrophilia and/or basophilia

Stephen E. Langabeer

JOURNAL OF CLINICAL PATHOLOGY (2023)

添加到收藏夹

Article Hematology

Imatinib Resistance in Chronic Myeloid Leukemia Associated with a D363G BCR::ABL1 Kinase Domain Mutation

Stephen E. Langabeer, Stuart Macleod, Una Bhreathnach, Kamal Fadalla

Summary: Acquired resistance to TKIs is a challenge in CML treatment, often caused by mutations in the BCR::ABL1 tyrosine kinase domain. A case of CML with a rare D363G BCR::ABL1 mutation is described, showing a suboptimal response to frontline imatinib but achieving sustained major molecular response with dasatinib and bosutinib. Reporting such cases is crucial for managing CML patients with this rare mutation in the future.

CASE REPORTS IN HEMATOLOGY (2023)

添加到收藏夹

Letter Oncology

Dual Drivers in the Myeloproliferative Neoplasms: An Underestimation?

Stephen E. Langabeer

TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2023)

添加到收藏夹

Review Pathology

Molecular diagnostic criteria of myeloproliferative neoplasms

Claire Andrews, Eibhlin Conneally, Stephen E. Langabeer

Summary: The genomic landscape of MPN has evolved with the integration of next-generation sequencing, which has become the gold standard for MPN management. Personalized diagnostics and prognostication have improved, but further research is needed to translate these molecular findings into targeted therapy and improve patient outcomes.

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2023)

添加到收藏夹

Letter Biochemical Research Methods

The JAK2V617F mutation and childhood type1 diabetic nephropathy?

Stephen E. Langabeer

BIOMEDICAL CHROMATOGRAPHY (2023)

添加到收藏夹

Letter Rheumatology

Molecular screening for an underlying myeloproliferative neoplasm in rheumatology patients

Stephen Langabeer

ARCHIVES OF RHEUMATOLOGY (2022)

添加到收藏夹

Letter Respiratory System

Screening for latent polycythemia vera in chronic obstructive pulmonary disease-associated erythrocytosis

Stephen E. Langabeer

RESPIRATORY MEDICINE AND RESEARCH (2022)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.